Market Place
Sourcing Support
FDA Advisory Committee To Review Stealth`s Elamipretide For Barth Syndrome
09 Sep 2024 //
PR NEWSWIRE
Stealth BioTherapeutics Completes Mid-Cycle Review For Elamipretide In Barth
29 Jul 2024 //
PR NEWSWIRE
Stealth Bio: First Patient In Phase 3 Elamipretide For Dry AMD
05 Jun 2024 //
PR NEWSWIRE
Stealth Biotherapeutics` Barth Syndrome NDA Receives Priority Review Designation
07 May 2024 //
PR NEWSWIRE
Stealth Bio gets FDA adcomm for previously rejected ultra-rare disease drug
09 Apr 2024 //
ENDPTS
Stealth Announces FDA Acceptance of NDA for Elamipretide for the Barth Syndrome
08 Apr 2024 //
PR NEWSWIRE
Stealth Announces Positive Phase 2 Meeting with FDA ragrading Elamipretide
12 Jun 2023 //
PR NEWSWIRE
Stealth BioTherapeutics Enters into Licensing Agreement with Pharmanovia
30 May 2023 //
PR NEWSWIRE
Stealth granted FDA meeting to revive elamipretide filing
15 Jun 2022 //
FIERCEBIOTECH
Stealth Announces Data from the Phase 2 ReCLAIM-2 Study of Elamipretide
23 May 2022 //
PRNEWSWIRE
Stealth BioTherapeutics Receives ODD for Elamipretide in DMD
12 May 2022 //
PRNEWSWIRE
Stealth Bio Posts Disappointing Data From Mid-Stage Geographic Atrophy Study
03 May 2022 //
BENZINGA
Stealth BioTherapeutics` Completes Phase 2 Geographic Atrophy Clinical Trial
15 Feb 2022 //
PRNEWSWIRE
Stealth BioTherapeutics Announces Oral Presentation of New DMD Data
08 Feb 2022 //
PRNEWSWIRE
Stealth rare disease drug denied by FDA in I told you so moment
21 Oct 2021 //
MARKETWATCH
Stealth BioTherapeutics Receives Refusal to File Letter from the FDA
20 Oct 2021 //
PRNEWSWIRE
Stealth Elamipretide NDA Tests Frontiers Of FDA’s Flexibility In Rare Diseases
03 Sep 2021 //
PINK SHEET
Stealth BioTherapeutics Announces Elamipretide Clinical Data
09 Dec 2020 //
PRNEWSWIRE
Stealth Biotherapeutics Announces $20M Financing to Advance Elamipretide
13 Apr 2020 //
PRNEWSWIRE
Stealth`s Announces +ve Results From Study to Evaluate Efficacy of Elamipretide
18 Feb 2020 //
PR NEWSWIRE
Stealth BioTherapeutics Presents Data for Elamipretide
17 Oct 2019 //
PR NEWSWIRE
Stealth CEO Share Excitement about Alexion Partnership and Potential of PMM Drug
17 Oct 2019 //
BIOSPACE
Alexion bags option on Stealth`s phase 3 rare disease drug
11 Oct 2019 //
FIERCE PHARMA
Stealth Announces Positive Results for Elamipretide in Ophthalmic Conditions
30 Apr 2019 //
PR NEWSWIRE
Stealth Bio Announces Dosing Of First Patient In Phase 2 Study Of Elamipretide
28 Mar 2019 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.